NAC has been shown in clinical trials to have a protective effect on inflammatory processes
Clinical Evidence Current clinical evidence for both peptides remains notably limited in comparison to the extensive body of preclinical data
By restoring this critical barrier, Larazotide prevents harmful substances from leaking into the bloodstream, reducing systemic inflammation and alleviating symptoms associated with leaky gut
Wood-Kaczmar, A., Gandhi, S
The Sikiric group has consistently characterized BPC-157 as resistant to degradation in human gastric juice, a property attributed to its compact 15-residue length, its five proline residues (which disrupt protease recognition motifs), and the absence of cysteine-bridgedependent tertiary structure (Sikiric et al., 2018)